Fulgent Genetics Inc. (FLGT)

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a sig...

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com...

Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. ...

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a yea...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.